Usefulness of Adiponectin as a Predictor of All Cause Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

Søren Østergaard Lindberg, Sune H Pedersen, Rasmus Møgelvang, Mette Bjerre, Jan Frystyk, Allan Flyvbjerg, Søren Galatius, Jan Skov Jensen

    49 Citations (Scopus)

    Abstract

    Substantial evidence points to a protective role of adiponectin against atherosclerosis and cardiovascular (CV) disease. However, in the setting of an acute myocardial infarction (AMI), the role of adiponectin has not previously been studied. Consequently, the aim of this study was to investigate the prognostic role of adiponectin after AMI in a large population of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. A total of 735 consecutive patients with ST-segment elevation myocardial infarction admitted to a single high-volume invasive heart center and treated with primary percutaneous coronary intervention from September 2006 to December 2008 were included. Blood samples were drawn immediately before the invasive procedure. Plasma adiponectin was measured using a validated immunoassay. End points were all-cause mortality, CV mortality, and admission for new AMI or heart failure. The median follow-up time was 27 months (interquartile range 22 to 33). Patients with high adiponectin (quartile 4) had increased mortality compared to patients with low adiponectin (quartiles 1 to 3) (log-rank p
    Original languageEnglish
    JournalAmerican Journal of Cardiology
    Volume109
    Issue number4
    Pages (from-to)492-496
    ISSN0002-9149
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Dive into the research topics of 'Usefulness of Adiponectin as a Predictor of All Cause Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention'. Together they form a unique fingerprint.

    Cite this